Fundamentals for Quest Diagnostics Incorporated
DGX's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an at...
Business Operations:
Sector: HealthcareIndustry: Diagnostics & Research
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, emerging retail healthcare providers, pharmaceutical companies and insurers, commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Revenue projections:
Financial Ratios:
| currentRatio | 1.700000 |
|---|---|
| forwardPE | 21.677494 |
| debtToEquity | 79.654000 |
| earningsGrowth | 0.287000 |
| revenueGrowth | 0.100000 |
| grossMargins | 0.331810 |
| operatingMargins | 0.149230 |
| trailingEps | 10.040000 |
| forwardEps | 11.977860 |
DGX's current ratio of 1.7, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as DGX has enough cash and current assets to handle its immediate liabilities comfortably.
DGX's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
Quest Diagnostics Incorporated's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that Quest Diagnostics Incorporated is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.
Price projections:
Insider Transactions:
17 sales transactions of Quest Diagnostics Incorporated were conducted, with market price at 209.90905492446.There were 3 buy transactions of Quest Diagnostics Incorporated stock, with market price at 196.2933349609375 per share.The insider transaction data shows no clear pattern or trend, making it difficult to draw any meaningful conclusions about the company's current direction based on this information.
Recommendation changes over time:
Quest Diagnostics Incorporated has garnered a buy bias from analysts recently, suggesting the stock is a good investment opportunity. This may lead to increased investor interest, as Quest Diagnostics Incorporated is seen as a reliable place to park money for those looking to benefit from potential market gains and company growth.